U.S. Markets close in 6 hrs 26 mins

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.16+0.09 (+1.67%)
As of 09:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.08
Bid4.90 x 1000
Ask5.72 x 800
Day's Range5.10 - 5.16
52 Week Range4.87 - 16.50
Avg. Volume120,683
Market Cap157.012M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 15, 2021
1y Target EstN/A
  • GlobeNewswire

    XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

    Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic CancerAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer. Enrollment in the Phase II portion is commencing immedia

  • GlobeNewswire

    XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer

    ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)] approved the launch of a multicenter randomized clinical study for XBiotech’s candidate cancer treatment Natrunix in combination with trifluridine/tipiraci

  • GlobeNewswire

    XBiotech Inks Clinical Manufacturing Deal

    XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & JohnsonAUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBiotech in December 2019. XBiotech discovers and develops therap